abstract |
The present invention relates to a heterotandem bicyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, conjugated to a second peptide ligand that binds to a component present on a cancer cell through a linker. . The present invention also relates to the use of the heterotandem bicyclic peptide complex in preventing, inhibiting or treating cancer. |